Seema Singhal

Grants

Grants per year 2003 2003 2005 2006 2007 2010 2021 2022 2027

• 11 Active
• 51 Finished

Grants per year

Search results

• Finished

  NU 22H01: Serial Monitoring of Circulating Plasma Cells and Plasma Cell Components in Adults with Plasma Cell Disorders

  Singhal, S. (PD/PI) & Singhal, S. (PD/PI)

  Menarini Silicon Biosystems, Inc.

  6/1/22 → 12/31/23

  Project: Research project

  • Circulating Plasma Cells 100%
  • Serial Monitoring 100%
  • Cell Components 100%
  • Cell-to-cell 100%
  • Plasma Cell Disorders 100%

• Prot #BB2121-MM-007: An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary Efficacy of bb2121 (Ide-cel) Combinations in Subjects with Relapsed/Refractory Multiple Myeloma (KarMMa-7)

  Singhal, S. (PD/PI)

  DrugDev Inc., Celgene Corporation

  8/6/21 → 8/6/24

  Project: Research project

• Prot #C1071003: MAGNETISMM-3: An Open-Label, Multicenter, Non-Randomized Phase 2 Study of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One Proteasome Inhibitor, One Immunomodulatory Drug and On

  Singhal, S. (PD/PI)

  Pfizer Inc.

  7/21/21 → 7/21/24

  Project: Research project

• Prot #209627: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/12/21 → 3/12/24

  Project: Research project

• Prot #209626: A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants with Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12)

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/10/21 → 3/10/24

  Project: Research project

• Prot #213304: Expanded Access Program for Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who are Refractory to a Proteasome Inhibitor, and an Immunomodulatory Agent, and an Anti-CD38 Antibody

  Singhal, S. (PD/PI)

  Quintiles, Inc., GlaxoSmithKline LLC

  3/11/20 → 3/11/23

  Project: Research project

• Prot #MK-3475-183: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM).

  Singhal, S. (PD/PI)

  Merck Sharp & Dohme Corporation

  1/26/17 → 1/26/20

  Project: Research project

• Prot #NEOD001-CL002: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care vs. Placebo Plus Standard of Care in Subjects with Light Chain (AL) Amyloidosis

  Singhal, S. (PD/PI)

  Covance Inc., Prothena Therapeutics Limited

  12/11/15 → 12/11/18

  Project: Research project

• Prot #54767414MMY3010: An Open-Label Treatment Use Protocol for Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or are Double Refractory to

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  10/23/15 → 10/23/18

  Project: Research project

• Prot #ARRAY-520-215:A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  ICON Clinical Research, LLC, Array BioPharma Incorporated

  5/5/15 → 5/5/18

  Project: Research project

• Prot #M12-901: A Phase 1b Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Relapsed or Refractory Multiple Myeloma Subjects who are Receiving Bortezomib and Dexamethasone as their Standard Therapy

  Singhal, S. (PD/PI)

  AbbVie Inc.

  9/25/14 → 9/25/17

  Project: Research project

• Prot #ARRAY-520-216: A Multicenter, Randomized, Open-label, Phase 2 Study of Carfilzomib With or Without ARRY-520 in Patients With Advanced Multiple Myeloma

  Singhal, S. (PD/PI)

  Array BioPharma Incorporated

  5/29/14 → 5/29/17

  Project: Research project

• Prot #54767414MMY2002: An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are

  Singhal, S. (PD/PI)

  Janssen Research & Development, LLC

  10/10/13 → 10/10/16

  Project: Research project

• Prot #FRF4998g: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of DFRF4539A in Patients with Relapsed or Refractory Multiple Myeloma.

  Singhal, S. (PD/PI)

  Genentech, Inc

  1/13/12 → 1/13/18

  Project: Research project

• Prot#2011-002: Carfilzomib Multiple Myeloma Expanded Access Protocol for Patients with Relapsed and Refractory Disease

  Singhal, S. (PD/PI)

  ACT Oncology, LLC, Onyx Pharmaceuticals, Inc.

  11/18/11 → 11/18/17

  Project: Research project

• A Genome Wide Admixture Scan of Multiple Myeloma in African-Americans

  Singhal, S. (PD/PI) & Mehta, J. (Co-Investigator)

  University of Southern California, National Cancer Institute

  8/1/10 → 5/31/15

  Project: Research project

• Prot# MFG4809g: An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients with Relapsed or Refractory t(4;14)-Positive Multiple Myeloma

  Singhal, S. (PD/PI)

  Genentech, Inc

  7/27/10 → 7/27/13

  Project: Research project

• Prot# PX-171-010: An Open-Label, Single-Arm, Phase 2 Study of Carfilzomib Maintenance Therapy in Subjects Previously Enrolled in Carfilzomib Treatment Protocols

  Singhal, S. (PD/PI)

  Onyx Pharmaceuticals, Inc.

  7/7/10 → 8/31/17

  Project: Research project

• PROT# PX-171-007: Phase 1b/2, Multicenter Open-Label Study of the Safety and Activity of Carfilzomib in Subjects with Relapsed Solid Tumors and in Multiple Myeloma

  Singhal, S. (PD/PI)

  Onyx Pharmaceuticals, Inc.

  6/17/10 → 6/17/17

  Project: Research project

• PROT# C18770/2043: An Open-Label Study to Determine the Maximum Tolerated Dose and Evaluate the Efficacy and Safety of CEP-18770 in Patients With Relapsed Multiple Myeloma Refractory to the Most Recent Therapy

  Singhal, S. (PD/PI)

  PPD Development, Cephalon, Inc.

  5/21/10 → 12/31/13

  Project: Research project

• PROT# PX-171-006: Phase 1b Multicenter Dose Escalation Study of Carfilzomib with Lenalidomide and Dexamethasone for Safety and Activity in Relapsed Multiple Myeloma

  Singhal, S. (PD/PI)

  Proteolix, Inc.

  9/14/09 → 12/31/13

  Project: Research project

• Prot# BIW-8962-001: Open-Label, Multi-Center, Dose Escalation, Phase 1/2 Study of Anti-GM2 Ganglioside Monoclonal Antibody BIW-8962 as Monotherapy in Subjects with Previously Treated Multiple Myeloma

  Singhal, S. (PD/PI)

  Kyowa Hakko Kirin Pharma, Inc.

  4/2/09 → 4/2/12

  Project: Research project

• Prot# A5481004: Phase 1/2 Open-Label Study of the Safety and Efficacy of PD 0332991 in Combination with Bortezomib and Dexamethasone in Patients with Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  INC Research, LLC, Pfizer Inc.

  9/22/08 → 9/22/11

  Project: Research project

• Prot# AURA-6202-011: An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) Translocation With or Without FGFR3 Expression

  Singhal, S. (PD/PI)

  Nerviano Medical Sciences S.r.l.

  8/7/08 → 11/7/11

  Project: Research project

• Prot# AVF4064g: A Randomized, Blinded, Placebo-Controlled, Multicenter, Phase II Study of Bevacizumab in Combination with Bortezomib in Patients with Relapsed or Refractory Multiple Myeloma

  Singhal, S. (PD/PI)

  PRA Health Sciences, Genentech, Inc

  1/10/08 → 1/10/11

  Project: Research project